Knowthestock.com
ALXN - Alexion Pharmaceuticals Inc.
SNP 500

Hold

Strong Growth and Stable

70%

based on last 5 year data.
Income Statement is STRONG
Revenue Growth is 18.84%
Operating Income Growth is -70.18%
Net Income Growth is -74.9%
Earnings Per Share (EPS) Growth is -74.58%
Net Margin is 9.94%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 3.59
Debt Ratio is 0.36
Current Debt to Net Income Ratio is 0.24
Total Debt to Total Assets Ratio is 0.14
Cash Flow is STRONG
Cash from Operations Growth is 44.03%
Capital Expenditure is Low
Net Increase in Cash is Positive
Long Term Score Trend is NEUTRAL
Investment Risk is Low
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Alexion Pharmaceuticals Inc. (ALXN) - https://alexion.com/
Exchange - NASDAQ/NGS (GLOBAL SELECT MARKET)
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Leonard Bell
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.